A Phase II Clinical Study of the Efficacy and Safety of Culmerciclib Rechallenge in HR-positive, HER2-negative Breast Cancer Patients With Resistance to First-line Endocrine Therapy.

NCT07666555 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

98

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: CDK4/6 inhibitor
DRUG: Culmerciclib
DRUG: Fulvestrant

Sponsor

Fudan University